Patrik Renblad
Director of Finance/CFO bij CANTARGIA AB
Profiel
Patrik Renblad is currently the Chief Financial Officer at Cantargia AB since 2023.
Prior to this, he was the Chief Financial Officer at SynAct Pharma AB from 2022 to 2023.
He also worked as a Finance Director-R&D at LEO Pharma A.
Mr. Renblad is a graduate of the University of Lund.
Actieve functies van Patrik Renblad
| Bedrijven | Functie | Begin |
|---|---|---|
| CANTARGIA AB | Director of Finance/CFO | 15-06-2023 |
Eerdere bekende functies van Patrik Renblad
| Bedrijven | Functie | Einde |
|---|---|---|
| SYNACT PHARMA AB | Director of Finance/CFO | 15-05-2023 |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | - |
Opleiding van Patrik Renblad
| University of Lund | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| CANTARGIA AB | Health Technology |
| SYNACT PHARMA AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
